Perspective Therapeutics, Inc. ('Perspective' or the 'Company') (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have ...

As the Trump administration upends federal research, Mizzou aims to raise more than $1 billion to build an advanced nuclear reactor to accelerate production of key ingredients for cancer treatments.

Bruce Power first began commercially producing Lutetium-177 in 2022, following the construction of an isotope production system at the plant's Unit 7 reactor, making it the world's first commercial ...

Prostate Cancer companies working in the treatment market are Telix Pharmaceuticals, Merck and Orion, Exelixis, Ipsen Pharma and Takeda, Pfizer, AstraZeneca, Kangpu Biopharmaceuticals, Merus, Blue ...

In the final overall survival analysis, researchers pitted Lu-177-PSMA-617 (Pluvicto) against an ARPI in the second-line ...

Donald Trump has branded masked protesters in public demonstrations as terrorists, while the ICE brigands wear required face ...

Radioligand therapy uses radio-labeled antibodies to deliver targeted radiation directly to prostate cancer cells, minimizing damage to healthy tissue, resulting in fewer and less grueling side ...

BWX Technologies (NYSE:BWXT) reached a record high Tuesday, closing +17.8% to lead nuclear-related stocks following reports that U.S. Secretary of Transportation and acting NASA administrator Sean ...

In comparison to Pluvicto ® (Lu-177-PSMA-617) and the majority of radiotherapies in development for prostate cancer, which target prostate specific membrane antigen (PSMA) and are either non ...

Additionally, it demonstrated greater efficacy than both Pluvicto (177Lu-PSMA-617) and Ac-225-PSMA-617 in laboratory and animal models. These findings highlight the potential of ATNM-400 in ...

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.